Navigation Links
FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS
Date:11/30/2009

to ten per million, or approximately 2,000 to 5,000 patients in the E.U. and 1,200 to 3,100 patients in the U.S. Approximately 50 percent of LEMS patients diagnosed have small cell lung cancer.

Patients with LEMS typically present with fatigue, muscle pain and stiffness. The weakness is generally more marked in the proximal muscles particularly of the legs and trunk. Other problems include reduced reflexes, drooping of the eyelids, facial weakness and problems with swallowing. Patients often report a dry mouth, impotence, constipation and feelings of light headedness on standing. On occasion these problems can be life threatening when the weakness involves respiratory muscles. A diagnosis of LEMS is generally made on the basis of clinical symptoms, electromyographic testing and the presence of autoantibodies against voltage gated calcium channels.

Current treatment of LEMS can consist of strategies directed at the underlying malignancy if one is present. Unfortunately, therapy of small cell lung cancer is limited and outcomes are generally poor. Immunosuppressive agents have been tried but success is limited by toxicity, and difficulty administering the regimens. A mainstay of therapy has been 3,4-DAP but its use in practice has been limited by the drug's availability. This problem will be addressed by the introduction of BioMarin's product.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan®
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Mirus Bio Awarded Grants & Contracts of Over $5 Million
2. FDA Grants Orphan Drug Designation to TREANDA, an Investigational Treatment for Chronic Lymphocytic Leukemia
3. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
4. NIH grants $750,000 to develop device to determine temperature of neonates brain
5. Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology
6. Radius Grants Major Pharmaceutical Company Exclusive Option to License BA058 for Osteoporosis
7. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
8. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
9. NASDAQ Panel Grants Merge Technologies Additional Time to Regain Compliance
10. FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208
11. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 2014 In keeping with the holiday ... bevy of last-minute Thanksgiving savings. The company is offering ... all product lines this holiday weekend as well as ... Friday, and Cyber Monday are right around the corner, ... both loyal customers and those looking to explore their ...
(Date:11/26/2014)... , Nov. 26, 2014 The ... from a survey of European physicians at the ... Innovation and Biological Therapies" at the Spanish Ministry ... hosted by EuropaBio and the Spanish Bioindustry Association ... Health, physicians from Spanish oncology and rheumatology societies, ...
(Date:11/26/2014)... 2014 PMG Research, Inc. announced ... is a network of sites that provide clinical research services ... million patient lives through its partnerships with large physician practices ... hub site locations in the Southeastern United States and spans ... the board will be held by: Dr. Robert ...
(Date:11/26/2014)... Silicon Valley Electronic Data Capture (EDC) ... Alliance , provider of clinical research and data management ... addition to its CRO Partnership Program, Clinovo expands ... India. , “We have found Clinovo’s ClinCapture to ... platform which is both user friendly and easy to ...
Breaking Biology Technology:DNA Spectrum Offers Last Minute Thanksgiving Coupons 2DNA Spectrum Offers Last Minute Thanksgiving Coupons 3ASBM Presents European Physicians Survey at Spanish Ministry of Health 2PMG Research Names Medical Advisory Board 2PMG Research Names Medical Advisory Board 3RPM Alliance Joins Clinovo’s CRO Partnership Program, Further Strengthening Its Presence in Southern California and India 2
... ,, A review of products for signal ... Activation of Signal Transduction Pathways with,PathDetect ... Mary Buchanan Chao-Feng Zheng ,Stratagene , ... such as,growth, differentiation, and coordination of cellular activities. ...
... streamlined and reliable method to obtain high-quality ... Basehore ,Stratagene , The StrataPrep ... quick, and reliable purification of bacteriophage single-stranded ... phage lysate exceeds the yield,obtained with the ...
... Preadipocytes and Differentiated Adipocytes ,,, A ... , Yuan-Di C. Halvorsen ,Zen-Bio, Inc. , ... , Regis Saladin , Ligand Pharmaceuticals ... , Stratagene introduces new tools to facilitate ...
Cached Biology Technology:Assess the In Vivo Activation of Signal Transduction Pathways with,PathDetect Reporting Systems 2Assess the In Vivo Activation of Signal Transduction Pathways with,PathDetect Reporting Systems 3Assess the In Vivo Activation of Signal Transduction Pathways with,PathDetect Reporting Systems 4Assess the In Vivo Activation of Signal Transduction Pathways with,PathDetect Reporting Systems 5Assess the In Vivo Activation of Signal Transduction Pathways with,PathDetect Reporting Systems 6Assess the In Vivo Activation of Signal Transduction Pathways with,PathDetect Reporting Systems 7Assess the In Vivo Activation of Signal Transduction Pathways with,PathDetect Reporting Systems 8Assess the In Vivo Activation of Signal Transduction Pathways with,PathDetect Reporting Systems 9Assess the In Vivo Activation of Signal Transduction Pathways with,PathDetect Reporting Systems 10Purified Single-Stranded M13 DNA for Automated Sequencing 2Purified Single-Stranded M13 DNA for Automated Sequencing 3Human Primary Preadipocytes and Differentiated Adipocytes 2Human Primary Preadipocytes and Differentiated Adipocytes 3Human Primary Preadipocytes and Differentiated Adipocytes 4Human Primary Preadipocytes and Differentiated Adipocytes 5Human Primary Preadipocytes and Differentiated Adipocytes 6
(Date:11/3/2014)... and preterm birth are linked to increased risk for ... the American College of Rheumatology (ACR) journal, Arthritis ... and pre-term babies were not at greater risk of ... According to the ACR, 27 million Americans over the ... of OA range from mild to severe and include ...
(Date:11/2/2014)... 2014)—In support of a bold quest to rid the ... Foundation today announced an award of US$156 million to ... in building new vaccines that will interrupt the cycle ... to zero" agenda. Such vaccines would ensure that parasite ... an "immunological bed net." , This approach to ...
(Date:11/2/2014)... and bump into a biologist . . . , While ... sketch, researchers have taken this premise and applied it to ... in the rising oceans of genomic data. , In this ... studies are publishing at a dizzying rate. The challenge is ... the noise (and there is no shortage of noise). , ...
Breaking Biology News(10 mins):Preterm, low birth-weight babies may need new hips in adulthood 2New malaria vaccines to prevent infection and block transmission get a shot in the arm 2New malaria vaccines to prevent infection and block transmission get a shot in the arm 3New malaria vaccines to prevent infection and block transmission get a shot in the arm 4Mutant models 2Mutant models 3Mutant models 4
... have believed that eating large amounts of protein made it ... the winner of five consecutive Olympic wrestling championships in the ... he built his crushing strength in part by consuming 20 ... go to such extremes, but Milo,s legacy survives in the ...
... cells, which make up 45 percent of blood, normally take ... side. But they can sometimes deform into an asymmetrical slipper ... explore how fluid flow might be responsible for this deformation, ... flow. The insights could help understand the mechanisms involved in ...
... 26, 2009 Results of an important new study ... at the time of cataract surgery increases a nutritional ... the development and/or progression of age-related macular degeneration (AMD). ... from the Macular Pigment Research Group at the Waterford ...
Cached Biology News:Moderate amounts of protein per meal found best for building muscle 2Blue light-filtering increases macular pigment, may protect against age-related vision loss 2Blue light-filtering increases macular pigment, may protect against age-related vision loss 3Blue light-filtering increases macular pigment, may protect against age-related vision loss 4
Recombinant Mouse Noggin...
...
Mouse Iduronate 2-Sulfatase Affinity Purified Polyclonal Ab Keywords: Sulfatases, Iduronate 2-Sulfatase, Mucopolysaccharidosis, Hunter Syndrome, Glycobiology Protein Family: Proteoglycan Regu...
Immunogen: Synthetic Peptide: C N(185) D G T E F G G S I Y Q K(197) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: